MX2021013573A - Metodos para elaborar anticuerpos. - Google Patents
Metodos para elaborar anticuerpos.Info
- Publication number
- MX2021013573A MX2021013573A MX2021013573A MX2021013573A MX2021013573A MX 2021013573 A MX2021013573 A MX 2021013573A MX 2021013573 A MX2021013573 A MX 2021013573A MX 2021013573 A MX2021013573 A MX 2021013573A MX 2021013573 A MX2021013573 A MX 2021013573A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- making antibodies
- antibodies
- libraries
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan, entre otros, métodos para mejorar el emparejamiento de una cadena pesada y una cadena liviana de un anticuerpo (tal como un anticuerpo biespecífico). También se proporcionan anticuerpos (por ejemplo, anticuerpos biespecíficos) generados usando dichos métodos, colecciones y métodos para cribar tales colecciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845594P | 2019-05-09 | 2019-05-09 | |
PCT/US2020/031914 WO2020227554A1 (en) | 2019-05-09 | 2020-05-07 | Methods of making antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013573A true MX2021013573A (es) | 2021-12-10 |
Family
ID=70919083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013573A MX2021013573A (es) | 2019-05-09 | 2020-05-07 | Metodos para elaborar anticuerpos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220056134A1 (es) |
EP (1) | EP3966244A1 (es) |
JP (2) | JP7397884B2 (es) |
KR (1) | KR20220005568A (es) |
CN (1) | CN113795514A (es) |
AR (1) | AR122263A1 (es) |
AU (1) | AU2020268399A1 (es) |
BR (1) | BR112021021673A2 (es) |
CA (1) | CA3134016A1 (es) |
IL (1) | IL287756A (es) |
MX (1) | MX2021013573A (es) |
SG (1) | SG11202110525QA (es) |
TW (2) | TWI796563B (es) |
WO (1) | WO2020227554A1 (es) |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
AU7104294A (en) | 1994-06-10 | 1996-01-05 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU715608B2 (en) | 1996-03-20 | 2000-02-03 | Morphosys Ag | Purification of tissue plasminogen activator (tPA) |
EP0954531A1 (en) | 1996-06-06 | 1999-11-10 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
WO1997047314A1 (en) | 1996-06-10 | 1997-12-18 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
EP0929361A4 (en) | 1996-10-04 | 2000-07-19 | Whatman Inc | DEVICE AND METHOD FOR SIMULTANEOUS MULTIPLE SYNTHESIS |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
AU745101B2 (en) | 1996-11-06 | 2002-03-14 | Genentech Inc. | Constrained helical peptides and methods of making same |
IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
RU2233878C2 (ru) | 1997-01-21 | 2004-08-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления |
DE69842174D1 (de) * | 1997-04-07 | 2011-04-21 | Genentech Inc | Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6416950B1 (en) | 1998-12-02 | 2002-07-09 | Phylos, Inc. | DNA-protein fusions and uses thereof |
EP1703893B1 (en) | 2003-12-23 | 2012-04-11 | Genentech, Inc. | Novel anti-il 13 antibodies and uses thereof |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
US9670269B2 (en) * | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
PL2173381T3 (pl) * | 2007-05-14 | 2014-03-31 | Novimmune Sa | Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
DE102008048942B4 (de) | 2008-09-25 | 2011-01-13 | Siemens Aktiengesellschaft | Anordnung mit einer Wellendichtung |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
AU2012245073B2 (en) * | 2011-04-21 | 2016-02-11 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using them b |
RU2644341C2 (ru) * | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Одноцепочечные антитела и другие гетеромультимеры |
EP2867253B1 (en) * | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
CA2893562C (en) | 2012-11-28 | 2023-09-12 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
WO2014150973A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3174897B1 (en) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
DK3608337T3 (da) * | 2014-08-04 | 2024-06-17 | Hoffmann La Roche | Bispecifikke T-celleaktiverende antigenbindende molekyler |
KR20240093813A (ko) | 2015-04-24 | 2024-06-24 | 제넨테크, 인크. | 다중특이적 항원-결합 단백질 |
EP3150637A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispecific antibodies |
EP3356406A1 (en) * | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
-
2020
- 2020-05-07 EP EP20729392.9A patent/EP3966244A1/en active Pending
- 2020-05-07 AU AU2020268399A patent/AU2020268399A1/en active Pending
- 2020-05-07 SG SG11202110525QA patent/SG11202110525QA/en unknown
- 2020-05-07 BR BR112021021673A patent/BR112021021673A2/pt unknown
- 2020-05-07 CA CA3134016A patent/CA3134016A1/en active Pending
- 2020-05-07 AR ARP200101299A patent/AR122263A1/es unknown
- 2020-05-07 WO PCT/US2020/031914 patent/WO2020227554A1/en unknown
- 2020-05-07 CN CN202080034498.7A patent/CN113795514A/zh active Pending
- 2020-05-07 MX MX2021013573A patent/MX2021013573A/es unknown
- 2020-05-07 KR KR1020217039917A patent/KR20220005568A/ko unknown
- 2020-05-07 JP JP2021565744A patent/JP7397884B2/ja active Active
- 2020-05-08 TW TW109115403A patent/TWI796563B/zh active
- 2020-05-08 TW TW112105232A patent/TW202346350A/zh unknown
-
2021
- 2021-11-01 IL IL287756A patent/IL287756A/en unknown
- 2021-11-08 US US17/454,015 patent/US20220056134A1/en active Pending
-
2023
- 2023-12-01 JP JP2023203630A patent/JP2024028811A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220056134A1 (en) | 2022-02-24 |
EP3966244A1 (en) | 2022-03-16 |
JP2022531437A (ja) | 2022-07-06 |
JP7397884B2 (ja) | 2023-12-13 |
IL287756A (en) | 2022-01-01 |
AU2020268399A1 (en) | 2021-10-28 |
AR122263A1 (es) | 2022-08-31 |
TWI796563B (zh) | 2023-03-21 |
KR20220005568A (ko) | 2022-01-13 |
SG11202110525QA (en) | 2021-10-28 |
CA3134016A1 (en) | 2020-11-12 |
CN113795514A (zh) | 2021-12-14 |
WO2020227554A1 (en) | 2020-11-12 |
BR112021021673A2 (pt) | 2021-12-21 |
JP2024028811A (ja) | 2024-03-05 |
TW202346350A (zh) | 2023-12-01 |
TW202108622A (zh) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
EA201792584A1 (ru) | Моноклональное антитело к pd-1 и способ его получения | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
EP1605058A4 (en) | METHOD FOR SCREENING A LIGHTWEIGHT CHAIN OF ANTIBODIES | |
EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
MX2022003744A (es) | Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas. | |
ZA202001114B (en) | Dynamic human heavy chain antibody libraries | |
MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
MX2022000137A (es) | Composiciones de anticuerpos para la ruptura de biopelículas. | |
MX2021014973A (es) | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. | |
MX2022003212A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso. | |
MX2022014166A (es) | Metodos para tratar el mieloma multiple. | |
EP3825334A4 (en) | HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3 | |
ZA202001112B (en) | Dynamic human antibody light chain libraries | |
BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
MX2023014458A (es) | Anticuerpos anti-ccr8 y usos de los mismos. | |
ZA202208337B (en) | A bispecific anti-pd-l1/vegf antibody and uses thereof | |
ZA202201796B (en) | Tetravalent symmetric bispecific antibody | |
MX2021000797A (es) | Anticuerpos agonistas de cd226. | |
MX2021013573A (es) | Metodos para elaborar anticuerpos. | |
MX2021012765A (es) | Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3. | |
MX2022000379A (es) | Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas. | |
MX2020014265A (es) | Anticuerpo variante que se une a cd38. | |
ZA202206670B (en) | Anti-ly6g6d antibodies and methods of use | |
GB202203066D0 (en) | Anti-rage antibody |